Cardiolipin Alterations during Obesity: Exploring Therapeutic Opportunities.
Alexandre ProlaFanny Pilot-StorckPublished in: Biology (2022)
Cardiolipin is a specific phospholipid of the mitochondrial inner membrane that participates in many aspects of its organization and function, hence promoting proper mitochondrial ATP production. Here, we review recent data that have investigated alterations of cardiolipin in different tissues in the context of obesity and the related metabolic syndrome. Data relating perturbations of cardiolipin content or composition are accumulating and suggest their involvement in mitochondrial dysfunction in tissues from obese patients. Conversely, cardiolipin modulation is a promising field of investigation in a search for strategies for obesity management. Several ways to restore cardiolipin content, composition or integrity are emerging and may contribute to the improvement of mitochondrial function in tissues facing excessive fat storage. Inversely, reduction of mitochondrial efficiency in a controlled way may increase energy expenditure and help fight against obesity and in this perspective, several options aim at targeting cardiolipin to achieve a mild reduction of mitochondrial coupling. Far from being just a victim of the deleterious consequences of obesity, cardiolipin may ultimately prove to be a possible weapon to fight against obesity in the future.
Keyphrases
- metabolic syndrome
- insulin resistance
- weight loss
- weight gain
- high fat diet induced
- type diabetes
- bariatric surgery
- oxidative stress
- adipose tissue
- gene expression
- obese patients
- roux en y gastric bypass
- uric acid
- electronic health record
- big data
- body mass index
- physical activity
- drug delivery
- cardiovascular risk factors
- machine learning
- mass spectrometry
- single molecule
- drug induced